<DOC>
	<DOCNO>NCT01782066</DOCNO>
	<brief_summary>Invasive meningococcal disease worldwide problem serious repercussion affect . Vaccination recognize best way combat . The cost vaccination prohibitive many low-resource setting home abroad . By harness special immunologic property skin , dose reduction may achieve intradermal administration vaccine . The cost saving associate dose reduction increase availability vaccine .</brief_summary>
	<brief_title>Dose-finding Safety 2 Intradermal MEN-ACYW135-conjugate Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Meningococcal C naive subject require fulfill follow criterion : Age ≥ 30 year Good health accord investigator Willingness ability adhere study regimen Able give inform consent Meningococcal C experience subject require fulfill follow criterion : Age ≥ 18 year Good health accord investigator Willingness ability adhere study regimen Able give inform consent Meningococcal C naïve subject : Known previous invasive meningococcal infection Known suspect previous vaccination meningococcal disease Known suspect allergy vaccine component Close contact last 60 day person know Neisseria positive History unusual severe reaction previous vaccination Family history GuillainBarré Syndrome Known suspect immune deficiency , either congenital acquire Administration plasma blood product less three month prior inclusion study Pregnancy ( breastfeed allow ) Fertile female conform prescribed contraceptive use ( await first menstruation vaccination get pregnant ) Any infectious disease Bleeding disorder use anticoagulant Participation subject another trial last 3 month Meningococcal C experience subject : Known suspect allergy vaccine component Known previous vaccination quadrivalent meningococcal vaccine ( either conjugate polysaccharide ) Close contact last 60 day person know Neisseria positive History unusual severe reaction previous vaccination Family history GuillainBarré Syndrome Known suspect immune deficiency , either congenital acquire Administration plasma blood product less three month prior inclusion study Pregnancy ( breastfeed allow ) Fertile female conform prescribed contraceptive use ( await first menstruation vaccination get pregnant ) Any infectious disease Bleeding disorder use anticoagulant Participation subject another trial last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>